These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36006011)

  • 1. Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    Loftus EV; Vermeire S; Feagan BG; Le Brun FO; Oortwijn A; Moerch U; Sandborn WJ; Hibi T
    J Crohns Colitis; 2023 Mar; 17(2):211-220. PubMed ID: 36006011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
    Dotan I; Feagan BG; Taliadouros V; Oortwijn A; Rudolph C; de Haas A; Santermans E; Hsieh J; Peyrin-Biroulet L; Hibi T
    J Crohns Colitis; 2023 Aug; 17(8):1207-1216. PubMed ID: 36928705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
    Schreiber S; Feagan BG; Peyrin-Biroulet L; Vermeire S; Faes M; Harris K; Oortwijn A; Daniele P; Patel H; Danese S
    J Crohns Colitis; 2023 Jun; 17(6):863-875. PubMed ID: 36756874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.
    Watanabe K; Peyrin-Biroulet L; Danese S; Fujitani Y; Faes M; Oortwijn A; Lindsay JO; Rogler G; Hibi T
    J Crohns Colitis; 2024 Jun; 18(6):801-811. PubMed ID: 38019901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study.
    Kobayashi T; Dignass A; Roblin X; Takatori Y; Kaise T; Oortwijn A; Jamoul C; Hibi T
    Intest Res; 2024 Jun; ():. PubMed ID: 39026439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
    Vermeire S; Feagan BG; Peyrin-Biroulet L; Oortwijn A; Faes M; de Haas A; Rogler G
    J Crohns Colitis; 2024 Jan; 18(1):54-64. PubMed ID: 37540206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
    Hibi T; Motoya S; Hisamatsu T; Hirai F; Watanabe K; Matsuoka K; Saruta M; Kobayashi T; Feagan BG; Tasset C; Besuyen R; Yun C; Crans G; Zhang J; Kondo A; Watanabe M
    Intest Res; 2023 Jan; 21(1):110-125. PubMed ID: 35263963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Danese S; Ferrante M; Feagan BG; Peyrin-Biroulet L; Hibi T; Sandborn WJ; Schreiber S; Ritter T; Loftus EV; Rogler G; Oortwijn A; Yun C; Le Brun FO; Dinoso J; Hsieh J; Vermeire S
    Am J Gastroenterol; 2023 Jan; 118(1):138-147. PubMed ID: 36113491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Akiyama S; Yokoyama K; Yagi S; Shinzaki S; Tsuruta K; Yoshioka S; Sako M; Shimizu H; Kobayashi M; Sakurai T; Nomura K; Shibuya T; Takahara M; Hiraoka S; Sugai K; Yanai S; Yoshida A; Koroku M; Omori T; Saruta M; Matsumoto T; Okamoto R; Tsuchiya K; Fujii T
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1413-1424. PubMed ID: 38494867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
    Feagan BG; Matsuoka K; Rogler G; Laharie D; Vermeire S; Danese S; Loftus EV; Beales I; Schreiber S; Kim HJ; Faes M; de Haas A; Masior T; Rudolph C; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2024 Sep; 60(5):563-584. PubMed ID: 39086130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
    Schreiber S; Rogler G; Watanabe M; Vermeire S; Maaser C; Danese S; Faes M; Van Hoek P; Hsieh J; Moerch U; Zhou Y; de Haas A; Rudolph C; Oortwijn A; Loftus EV
    Aliment Pharmacol Ther; 2023 Nov; 58(9):874-887. PubMed ID: 37718932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
    N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1.
    Loftus EV; Sands BE; Colombel JF; Dotan I; Khalid JM; Tudor D; Geransar P
    Clin Exp Gastroenterol; 2020; 13():211-220. PubMed ID: 32606883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
    Lichtenstein GR; Cohen BL; Salese L; Modesto I; Wang W; Chan G; Ahmed HM; Su C; Peyrin-Biroulet L
    Dig Dis Sci; 2023 Jun; 68(6):2624-2634. PubMed ID: 36739367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    van Asselt ADI; Armstrong N; Kimman M; Peeters A; McDermott K; Stirk L; Ahmadu C; Govers TM; Hoentjen F; Joore MA; Grimm SE
    Pharmacoeconomics; 2023 Mar; 41(3):239-251. PubMed ID: 36725788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
    Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.